LORLAMAKS25 Drug name: Lorlatinib tablets/Lorlatinib

The following is the general instructions for Lorlatinib, which is for reference only. For specific use, please refer to the instructions in the drug packaging and follow the doctor's instructions.

---

Drug Name

Generic Name: Lorlatinib
Product Name: LORLAMAK

---

Indications

Lorlatinib is a tyrosine kinase inhibitor indicated for the following conditions:

• Non-small cell lung cancer (NSCLC) :
  It is used to treat patients with locally advanced or metastatic non-small cell lung cancer who have an ALK (anaplastic lymphoma kinase) mutation, usually in patients whose disease has progressed after treatment with a first- or second-generation ALK inhibitor (such as crizotinib, alectinib, or brigatinib).

---

Mechanism of action

Lorlatinib selectively inhibits the activity of ALK and ROS1 tyrosine kinases, blocking abnormally activated signal transduction pathways, thereby inhibiting the growth and survival of tumor cells.

---

Dosage

• Recommended dose : 100 mg orally once daily.
• Dosage : Can be taken with or without food. Tablets should be swallowed whole and should not be crushed, chewed or split.

Dosage adjustments :
If drug-related adverse reactions occur, your doctor may adjust the dose, usually reducing it to 75 mg/day or 50 mg/day.

---

Precautions

1. Genetic testing :
   • Before starting treatment, it is necessary to confirm whether the patient's tumor has an ALK-positive mutation.
2. Side Effect Monitoring :
   • Common side effects : hypercholesterolemia, hypertriglyceridemia, peripheral neuropathy, fatigue, weight gain, gastrointestinal symptoms (such as diarrhea, nausea, vomiting), etc.
   • Serious side effects : abnormal liver function, prolonged QT interval on the electrocardiogram, central nervous system toxicity (such as cognitive impairment, language disorders, mood changes), hyperlipidemia, etc.
3. Use in special populations :
   • Pregnant and lactating women : Do not use, may cause serious harm to the fetus or infant.
   • Children : Safety and effectiveness have not been established.
   • Elderly : The dose should be adjusted according to the patient's condition and close monitoring is required.
4. Monitoring recommendations :
   • Lipid levels : Cholesterol and triglyceride levels should be monitored at the start of treatment and periodically during treatment.
   • Cardiac monitoring : Monitor QT interval and heart rate.
   • Neurotoxicity : Monitor for neurological symptoms, such as memory or language problems.

---

Drug interactions

1. CYP3A4 inducers or inhibitors :
   • Avoid concomitant use of strong CYP3A4 inducers (e.g., rifampin), which may reduce the efficacy of lorlatinib.
   • Coadministration with CYP3A4 inhibitors may increase the risk of adverse reactions of lorlatinib.
2. Drug interactions :
   • Caution is advised when using other drugs that may affect the QT interval.

---

Contraindications

• Patients who are allergic to lorlatinib or its excipients are contraindicated.
• It should be used with caution in patients with a history of significant QT prolongation.

---

Storage conditions

• Store in a dry environment at 20°C to 25°C.
• Avoid high temperature, humidity and direct sunlight. Keep out of reach of children.

---

Important Tips

• The use of lorlatinib should be carried out under the guidance of a physician with experience in tumor treatment.
• If serious adverse reactions occur (such as severe neurological toxicity or abnormal heart rhythm), the drug should be stopped immediately and the doctor should be contacted.

---

Note : For more detailed information or special case dosing regimens, please consult your doctor or pharmacist. If you need further instructions, please let me know!